MODUS THERAPEUTICS HLDG
MODUS THERAPEUTICS HLDG
Share · SE0015987904 · A3CVSY (XSTO)
Overview
No Price
Closing Price XSTO 09.12.2025: 0,36 SEK
18.12.2025 07:04
Current Prices from MODUS THERAPEUTICS HLDG
ExchangeTickerCurrencyLast TradePriceDaily Change
XFRA: Frankfurt
Frankfurt
99Z.F
EUR
18.12.2025 07:04
0,02 EUR
-0,0006 EUR
-3,03 %
XSTO: NASDAQ STOCKHOLM AB
NASDAQ STOCKHOLM AB
MODTX.ST
SEK
09.12.2025 08:39
0,36 SEK
0,003 SEK
+0,84 %
Share Float & Liquidity
Free Float 29,11 %
Shares Float 26,54 M
Shares Outstanding 91,16 M
Company Profile for MODUS THERAPEUTICS HLDG Share
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Get up to date insights from finAgent about MODUS THERAPEUTICS HLDG

Company Data

Name MODUS THERAPEUTICS HLDG
Company Modus Therapeutics Holding AB (publ)
Website https://www.modustx.com
Primary Exchange XSTO Frankfurt
WKN A3CVSY
ISIN SE0015987904
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO John Öhd
Market Capitalization 31 Mio
Country Sweden
Currency EUR
Employees 0,0 T
Address Olof Palmes gata 29 IV, 11122 Stockholm
IPO Date 2021-07-22

Ticker Symbols

Name Symbol
NASDAQ STOCKHOLM AB MODTX.ST
Frankfurt 99Z.F
More Shares
Investors who hold MODUS THERAPEUTICS HLDG also have the following shares in their portfolio:
BGF-EURO BOND NAM. A2
BGF-EURO BOND NAM. A2 Fund
MORGAN SINDALL GRP
MORGAN SINDALL GRP Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025